Even as analysts and investors scrutinized detailed phase III findings from its triple-G obesity candidate, retatrutide, Eli ...

Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib produced more than two-and-a-half times the complete ...

Pharma companies are contributing proprietary data to feed a foundation AI model that will predict at the earliest stages of ...

Xeltis BV has begun commercialization of Axess, its vascular access conduit for hemodialysis in Germany and Iberia, and ...

As part of a broader effort to prune its pipeline, Roche Holding AG and its Genentech unit ended development of two licensed ...

At this year’s meeting of the American Society of Clinical Oncology in Chicago, Aprea Therapeutics Inc. made a splash with ...

At the ongoing European Association for the Study of Diabetes (EASD) meeting, researchers showcased a new generation of experimental therapies that move beyond traditional appetite and insulin ...

Pancreatic tumors have historically been a hard-to-treat cancer because of the late stage of onset and lack of targeted therapies. At the American Association for Cancer Research Conference on ...

Tolerance Bio Inc. struck its second major licensing deal in six weeks, acquiring global development rights and ex-Japan commercialization rights to Tanabe Pharma Corp.’s clinical-stage ...

Newco Aptadir Therapeutics Srl raised €40 million (US$45.3 million) in a seed round to take forward a new class of RNA ...

The latest phase I/II hurdle for Uniqure NV with ifezuntirgene inilparvovec (ifez-inil) in Huntington’s disease (HD) led to ...

China’s medtech sector seems to be an emerging threat to the Western companies. After all, it has already become a global ...